MedTrace Logo

Immuno-effect of Tα1 for Stage I NSCLC

NCT06598839 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-09-19

No results posted yet for this study

Summary

To explore the effect of thymosin alpha 1 (Tα1) on postoperative peripheral blood circulating tumor cells and immunosenescence in patients with early-stage non-small cell lung cancer (NSCLC).

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Thymosin Alpha1

subcutaneous injection of Tα1, 1.6mg each time, biw, for 3 months

Sponsors & Collaborators

  • Yousheng Mao

    lead OTHER

Principal Investigators

  • Yousheng Mao · National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2025-09-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06598839 on ClinicalTrials.gov